Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PBGENE-LLY3
- Development stage
- Discontinued
- Lead developer
- Precision BioSciences
- Modality
- Gene Therapies
- Administration
- Unknown
01
Overview
PBGENE-LLY3 is an investigational gene editing therapy developed by Precision BioSciences for central nervous system (CNS) related disorders. It employs the ARCUS gene editing platform, which is based on proprietary meganucleases engineered to enable targeted gene modification. PBGENE-LLY3 is designed as a CNS-directed gene modulator, aiming to correct, modulate, or eliminate disease-driving genetic defects within the nervous system. As of 2025, development was discontinued at a preclinical phase. Details about the exact target gene or specific CNS disease indication have not been publicly disclosed.
- Brand names
- PBGENE-LLY3PBGENE-LLY-3PBGENE-LLY 3
- Other names
- PBGENE-LLY3PBGENE-LLY-3PBGENE-LLY 3PBGENELLY3PBGENELLY-3PBGENELLY 3
Beyond the preview
Go deeper on PBGENE-LLY3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PBGENE-LLY3.